Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4135993 | 0.90 | TLR7 (0.79) | TLR7IL6 | |
| SCHEMBL26347160 | 0.88 | TLR7 (0.84) | TLR7IL6 | |
| SCHEMBL4800608 | 0.87 | TLR7 (0.68) | TLR7IL6 | |
| SCHEMBL20756317 | 0.87 | TLR7 (0.73) | TLR7IL6 | |
| SCHEMBL13871713 | 0.86 | TLR7 (0.68) | TLR7IL6 | |
| SCHEMBL13849553 | 0.86 | TLR7 (0.62) | TLR7IL6 | |
| SCHEMBL1146480 | 0.85 | TLR7 (0.75) | TLR7IL6 | |
| SCHEMBL4135437 | 0.85 | TLR7 (0.75) | TLR7IL6 | |
| SCHEMBL13849548 | 0.84 | TLR7 (0.69) | TLR7IL6 | |
| SCHEMBL13871719 | 0.84 | TLR7 (0.67) | TLR7IL6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110028715-A1 | NOVEL ADENINE COMPOUND | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2011-02-03 | — | — | US | claimed |
| US-20100093998-A1 | NOVEL ADENINE COMPOUND | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2010-04-15 | — | — | US | claimed |
| EP-2133353-A1 | NOVEL ADENINE COMPOUND | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2009-12-16 | — | — | EP | claimed |
| US-20110028715-A1 | NOVEL ADENINE COMPOUND | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2011-02-03 | — | — | US | disclosed |
| US-20100093998-A1 | NOVEL ADENINE COMPOUND | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2010-04-15 | — | — | US | disclosed |
| US-20100093998-A1 | NOVEL ADENINE COMPOUND | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2010-04-15 | — | — | US | disclosed |
| EP-2133353-A1 | NOVEL ADENINE COMPOUND | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2009-12-16 | — | — | EP | disclosed |
| EP-2133353-A1 | NOVEL ADENINE COMPOUND | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2009-12-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028715-A1 | NOVEL ADENINE COMPOUND | NR0B2, NR0B1, BRD7 | TLR7 4/4885IL6 3123/4885 |
| US-20100093998-A1 | NOVEL ADENINE COMPOUND | NR0B2, NR0B1, BRD7 | TLR7 4/4885IL6 3201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.